NASDAQ:PRAH - PRA Health Sciences Stock Price, Forecast & News

PRA Health Sciences' stock was trading at $88.68 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PRAH shares have decreased by 11.5% and is now trading at $78.51. View which stocks have been mosted impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for PRA Health Sciences.

PRA Health Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for PRA Health Sciences.

PRA Health Sciences Inc (NASDAQ:PRAH) announced its quarterly earnings results on Thursday, February, 20th. The medical research company reported $1.54 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.32 by $0.22. The medical research company earned $800.24 million during the quarter, compared to the consensus estimate of $794.91 million. PRA Health Sciences had a net margin of 7.93% and a return on equity of 28.52%. The firm's quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.31 earnings per share. View PRA Health Sciences' earnings history.

PRA Health Sciences updated its FY20 earnings guidance on Thursday, February, 20th. The company provided earnings per share guidance of $5.77-5.97 for the period, compared to the Thomson Reuters consensus estimate of $5.81. The company issued revenue guidance of $3.23-3.36 billion, compared to the consensus revenue estimate of $3.32 billion.

9 analysts have issued 1 year price targets for PRA Health Sciences' shares. Their forecasts range from $89.00 to $128.00. On average, they anticipate PRA Health Sciences' share price to reach $110.38 in the next twelve months. This suggests a possible upside of 40.6% from the stock's current price. View analysts' price targets for PRA Health Sciences.

News headlines about PRAH stock have trended extremely negative on Sunday, according to InfoTrie. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. PRA Health Sciences earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutPRA Health Sciences.

PRA Health Sciences saw a decline in short interest in the month of February. As of February 28th, there was short interest totaling 1,910,000 shares, a decline of 14.7% from the February 13th total of 2,240,000 shares. Based on an average daily trading volume, of 521,200 shares, the days-to-cover ratio is currently 3.7 days. Currently, 3.3% of the shares of the stock are sold short. View PRA Health Sciences' Current Options Chain.

Some companies that are related to PRA Health Sciences include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), PPD (PPD), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Precigen (PGEN), Intrexon (XON), Auxly Cannabis Group (CBWTF), Anavex Life Sciences (AVXL) and Luna Innovations (LUNA).

Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Adobe (ADBE), Paypal (PYPL), Applied Materials (AMAT), Veeva Systems (VEEV), Lam Research (LRCX), Walt Disney (DIS), Netflix (NFLX) and Broadcom (AVGO).

(PRAH) raised $306 million in an initial public offering on Thursday, November 13th 2014. The company issued 17,000,000 shares at $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

PRA Health Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include Capital Research Global Investors (4.07%), Janus Henderson Group PLC (3.10%), Massachusetts Financial Services Co. MA (2.70%), State Street Corp (2.27%), Pendal Group Ltd (1.52%) and Standard Life Aberdeen plc (1.23%). Company insiders that own PRA Health Sciences stock include Fund Holdings LP Kkr and Pra Investors LP Kkr. View institutional ownership trends for PRA Health Sciences.

PRAH stock was sold by a variety of institutional investors in the last quarter, including Standard Life Aberdeen plc, Bank of New York Mellon Corp, AQR Capital Management LLC, Pictet Asset Management Ltd., Capital Research Global Investors, Artemis Investment Management LLP, Acadian Asset Management LLC, and Strs Ohio. View insider buying and selling activity for PRA Health Sciences.

PRAH stock was bought by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Norges Bank, Janus Henderson Group PLC, Captrust Financial Advisors, FMR LLC, Goldman Sachs Group Inc., Mackay Shields LLC, and Assenagon Asset Management S.A.. View insider buying and selling activity for PRA Health Sciences.

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PRAH stock can currently be purchased for approximately $78.51.

PRA Health Sciences has a market capitalization of $4.99 billion and generates $3.07 billion in revenue each year. The medical research company earns $243.02 million in net income (profit) each year or $4.80 on an earnings per share basis. PRA Health Sciences employs 17,500 workers across the globe. View additional information about PRA Health Sciences.

The official website for PRA Health Sciences is http://www.prahs.com/.

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]